The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Anticholinergics for symptomatic management of Parkinson´s disease
Open accessAbstract
BACKGROUND: Anticholinergics were the first drugs available for the symptomatic treatment of Parkinson's disease and they are still widely used today, both as monotherapy and as part of combination regimes. They are commonly believed to be associated with a less favourable side effect profile than other antiparkinsonian drugs, in particular with respect to neuropsychiatric and cognitive adverse events. They have been claimed to exert a better effect on tremor than on other parkinsonian features. OBJECTIVES: To determine the efficacy and tolerability of anticholinergics in the symptomatic treatment of Parkinson's disease compared to placebo or no treatment. SEARCH STRATEGY: The literature search included electronic searches of the Cochrane Controlled Trials Register (The Cochrane Library, Issue 4, 2001), MEDLINE (1966 to 2001), Old Medline (1960-1965), Index Medicus (1927 - 1959), as well as handsearching the neurology literature including the reference lists of identified articles, other reviews and book chapters. SELECTION CRITERIA: Randomised controlled trials of anticholinergic drugs versus placebo or no treatment in de-novo or advanced Parkinson's disease, either as monotherapy or as an add-on to other antiparkinsonian drugs were included. Trials of anticholinergic drugs that were never in general clinical use were excluded. DATA COLLECTION AND ANALYSIS: Data was abstracted independently by two authors. Differences were settled by discussion among all authors. Data collected included patient characteristics, disease duration and severity, concomitant medication, interventions including duration and dose of anticholinergic treatment, outcome measures, rates of and reasons for withdrawals, and neuropsychiatric and cognitive adverse events. MAIN RESULTS: The initial search yielded 14 potentially eligible studies, five of which were subsequently excluded. In three cases this was because they dealt with substances that had never been marketed or had not been licensed for as far as could be traced back. One trial had been published twice in different languages. One study was excluded based on the assessment of its methodological quality. The remaining nine studies were all of double-blind cross-over design and included 221 patients. Trial duration was between five and 20 weeks and drugs investigated were benzhexol (mean doses: 8 to 20 mg/d), orphenadrine (mean dose not reported), benztropine (mean dose not reported), bornaprine (8 to 8.25 mg/d), benapryzine (200 mg/d), and methixine (45 mg/d). Only one study involved two anticholinergic drugs. Outcome measures varied widely across studies and in many cases, the scales applied were the authors' own and were not defined in detail. Incomplete reporting of methodology and results was frequent. The heterogeneous study designs as well as incomplete reporting precluded combined statistical analysis. Five studies used both tremor and other parkinsonian features as outcome measures. Outcome measures in these five studies were too different for a combined analysis and results varied widely, from a significant improvement in tremor only to significant improvement in other features but not in tremor. All studies except one (dealing with methixine) found a significant improvement from baseline on the anticholinergic drug in at least one outcome measure. The difference between placebo and active drug was reported in four studies and was found to be significant in all cases. No study failed to show superiority of the anticholinergic over placebo. The occurrence of neuropsychiatric and cognitive adverse events was reported in all but three studies (in 35 patients on active drug versus 13 on placebo). The most frequently reported reason for drop-outs from studies was in patients on placebo due to withdrawal from pre-trial anticholinergic treatment. REVIEWER'S CONCLUSIONS: As monotherapy or as an adjunct to other antiparkinsonian drugs, anticholinergics are more effective than placebo in improving motor function in Parkinson's disease. Neuropsychiatric and cognitive adverse events occur more frequently on anticholinergics than on placebo and are a more common reason for withdrawal than lack of efficacy. Results regarding a potentially better effect of the anticholinergic drug on tremor than on other outcome measures are conflicting and data do not strongly support a differential clinical effect on individual parkinsonian features. Data is insufficient to allow comparisons in efficacy or tolerability between individual anticholinergic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memory and cognitive function in man: Does the cholinergic system have a specific role?
DRACHMAN, D. A. (1977) · Neurology · doi:10.1212/wnl.27.8.783 · Cited by 614
Critical analysis of the disability in Parkinson's disease.
Webster, D. D. (1968) · PubMed · Cited by 488
Cholinergic‐dependent cognitive deficits in Parkinson's disease
Dubois, B., Danzé, F., Pillon, B., Cusimano, G., Lhermitte, F., & Agid, Y. (1987) · Annals of Neurology · doi:10.1002/ana.410220108 · Cited by 178
Confusion, dementia and anticholinergics in Parkinson's disease.
de Smet, Y., Ruberg, M., Serdaru, M., Dubois, B., Lhermitte, F., & Agid, Y. (1982) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.45.12.1161 · Cited by 133
Evidence-based Medicine Workbook
Mar, C. D., & Glasziou, P. (2003) · Cited by 39
Anticholinergic Drugs and Amantadine in the Treatment of Parkinson’s Disease
Lang, A. E., & Blair, R. D. G. (1989) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-73899-9_12 · Cited by 27
The Evidence Based Medicine Workbook: Critical Appraisal For Clinical Problem Solving
Dixon, R. A., Munro, J. F., & Silcocks, P. (1997) · Medical Entomology and Zoology · Cited by 27
KR 339 IN THE TREATMENT OF PARKINSONIAN TREMOR
Iivanainen, M. V. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1974.tb02794.x · Cited by 15
Rix, A. (1977) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-2511-6_18 · Cited by 5
Cited by
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Muscarinic acetylcholine receptors as CNS drug targets
Langmead, C. J., Watson, J., & Reavill, C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.009 · Cited by 419
Advances in the treatment of Parkinson's disease
Singh, N., Pillay, V., & Choonara, Y. E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.009 · Cited by 394
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Jost, S. T., Kaldenbach, M., Antonini, A., Martinez‐Martin, P., Timmermann, L., Odin, P., Katzenschlager, R., Borgohain, R., Fasano, A., Stocchi, F., et al. (2023) · Movement Disorders · doi:10.1002/mds.29410 · Cited by 389
Self-citation
Metadata
- Authors
- Katzenschlager, R., Sampaio, C., Costa, J., & Lees, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2002-07-22
- Volume
- 2010
- Issue
- 1
- Pages
- CD003735-CD003735
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2116294828
- Cited by
- 259
- References
- 9
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anticholinergics for symptomatic management of Parkinson´s disease. https://app.cochat.ai/papers/10.1002/14651858.cd003735
- The paper
- Katzenschlager, R., Sampaio, C., Costa, J., & Lees, A. (2002). Anticholinergics for symptomatic management of Parkinson´s disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003735
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.